



Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Yue Zhou^{1,2,3†}, Qing Zhang^{1,2,3,4†}, Minjia Wang^{1,2,3,5†}, Chengzhi Huang^{2,3,5*†} and Xueqing Yao^{1,2,3,5*}

¹ The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China, ² Department of Gastrointestinal Surgery, Ganzhou Municipal Hospital, Ganzhou, China, ³ Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, ⁴ Department of Gastrointestinal and Anorectal Surgery, The First People's Hospital of Zhaoqing, Zhaoqing, China, ⁵ School of Medicine, South China University of Technology, Guangzhou, China

Keywords: oxaliplatin, chemoresistance, siRNA delivery, colorectal cancer, ATP7A

OPEN ACCESS

Edited and reviewed by:

Zeming Liu,
Huazhong University of Science and
Technology, China

*Correspondence:

Xueqing Yao
sy Yao xueqing@scut.edu.cn
Chengzhi Huang
huangchengzhi93@hotmail.com

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Oncology

Received: 10 April 2022

Accepted: 09 May 2022

Published: 27 June 2022

Citation:

Zhou Y, Zhang Q, Wang M, Huang C
and Yao X (2022) Corrigendum:
Effective Delivery of siRNA-Loaded
Nanoparticles for Overcoming
Oxaliplatin Resistance in
Colorectal Cancer.
Front. Oncol. 12:916983.
doi: 10.3389/fonc.2022.916983

A Corrigendum on:

Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

By Zhou Y, Zhang Q, Wang M, Huang C and Yao X (2022). *Front. Oncol.* 12:827891. doi: 10.3389/fonc.2022.827891

In the original article, there was a mistake in **Figure 3** as published. While preparing the figures, the labels of the bar charts in **Figure 3** were misspelled. The corrected **Figure 3** appears below.

In the published article, there was also an error in affiliation 3. Instead of “Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China”, it should be “Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China”.

There was a further error as an affiliation was omitted for authors Minjia Wang, Chengzhi Huang and Xueqing Yao. These authors should also have affiliation 5 – “School of Medicine, South China University of Technology, Guangzhou, China”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhou, Zhang, Wang, Huang and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 3 | Knockdown of ATP7A expression may inhibit cancer tumorigenesis *in vitro* (A) Colony formation assays in HCT116 and LOVO cells. (B) A flow cytometer was performed to assess the apoptosis rate of HCT116 and LOVO cells. (C) Wound healing assay of HCT116 and LOVO cells. (D) Transwell assay was performed to evaluate the invasion of HCT116 and LOVO cells. **P < 0.01 and ***P < 0.001 when compared to the control group.